{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:04Z","timestamp":1793119624457,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T00:00:00Z","timestamp":1751760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-08638-3","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T08:50:40Z","timestamp":1751791840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Abbas","family":"Al Mutair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Alhumaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gasmelseed Y.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Rabaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Alkubati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdan","family":"Albaqawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awatif M.","family":"Alrasheeday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawther","family":"Alsaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mottershead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Daniyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awad","family":"Al-Omari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,6]]},"reference":[{"issue":"7798","key":"8638_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798), 270\u2013273 (2020).","journal-title":"Nature"},{"key":"8638_CR2","doi-asserted-by":"crossref","unstructured":"The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 4: 536\u2013544 (2020).","DOI":"10.1038\/s41564-020-0695-z"},{"issue":"2","key":"8638_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/sccj.sccj_15_20","volume":"4","author":"W Alhazzani","year":"2020","unstructured":"Alhazzani, W. et al. The Saudi critical care society clinical practice guidelines on the management of COVID-19 patients in the intensive care unit. Saudi Crit. Care J. 4(2), 27\u201344 (2020).","journal-title":"Saudi Crit. Care J."},{"issue":"11","key":"8638_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jiph.2020.09.003","volume":"13","author":"A Al-Omari","year":"2020","unstructured":"Al-Omari, A. et al. Clinical characteristics of non-intensive care unit COVID-19 patients in Saudi Arabia: A descriptive cross-sectional study. J. Infect. Public Health 13(11), 1639\u20131644 (2020).","journal-title":"J. Infect. Public Health"},{"key":"8638_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-020-00462-x","volume":"25","author":"A Al Mutair","year":"2020","unstructured":"Al Mutair, A. et al. Clinical, epidemiological, and laboratory characteristics of mild-to-moderate COVID-19 patients in Saudi Arabia: An observational cohort study. Eur. J. Med. Res. 25, 1\u20138 (2020).","journal-title":"Eur. J. Med. Res."},{"issue":"1","key":"8638_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jiph.2020.11.002","volume":"14","author":"JM AlJishi","year":"2021","unstructured":"AlJishi, J. M. et al. Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia. J. Infect. Public Health 14(1), 6\u201311 (2021).","journal-title":"J. Infect. Public Health"},{"issue":"3","key":"8638_CR7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2991\/jegh.k.200806.002","volume":"10","author":"M Barry","year":"2020","unstructured":"Barry, M. et al. Clinical characteristics and outcome of hospitalized COVID-19 patients in a MERS-CoV endemic area. J. Epidemiol. Glob. Health 10(3), 214\u2013221 (2020).","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"2","key":"8638_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2991\/jegh.k.210112.001","volume":"11","author":"S AlBahrani","year":"2021","unstructured":"AlBahrani, S. et al. A case series of severe hospitalized COVID-19 patients treated with tocilizumab and glucocorticoids: A report from Saudi arabian hospital. J. Epidemiol. Glob. Health 11(2), 233\u2013237 (2021).","journal-title":"J. Epidemiol. Glob. Health"},{"issue":"26","key":"8638_CR9","first-page":"5154","volume":"121","author":"DT Teachey","year":"2013","unstructured":"Teachey, D. T. et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood J. Am. Soc. Hematol. 121(26), 5154\u20135157 (2013).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"6490","key":"8638_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368(6490), 473\u20134 (2020).","journal-title":"Science"},{"issue":"10229","key":"8638_CR11","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta, P. et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet 395(10229), 1033\u20131034 (2020).","journal-title":"The Lancet"},{"issue":"8","key":"8638_CR12","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1016\/S2665-9913(20)30173-9","volume":"2","author":"G Guaraldi","year":"2020","unstructured":"Guaraldi, G. et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol. 2(8), e474\u2013e484 (2020).","journal-title":"Lancet Rheumatol."},{"issue":"8","key":"8638_CR13","doi-asserted-by":"publisher","first-page":"e0237693","DOI":"10.1371\/journal.pone.0237693","volume":"15","author":"A Ip","year":"2020","unstructured":"Ip, A. et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients: An observational study. PLoS ONE 15(8), e0237693 (2020).","journal-title":"PLoS ONE"},{"issue":"18","key":"8638_CR14","first-page":"1824","volume":"323","author":"JM Sanders","year":"2020","unstructured":"Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 323(18), 1824\u20131836 (2020).","journal-title":"JAMA"},{"issue":"2","key":"8638_CR15","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","volume":"73","author":"EC Somers","year":"2021","unstructured":"Somers, E. C. et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin. Infect. Dis. 73(2), e445\u2013e454 (2021).","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"8638_CR16","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/jmv.25964","volume":"92","author":"R Alattar","year":"2020","unstructured":"Alattar, R. et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J. Med. Virol. 92(10), 2042\u20132049 (2020).","journal-title":"J. Med. Virol."},{"issue":"12","key":"8638_CR17","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3855\/jidc.15350","volume":"15","author":"DA Obeid","year":"2021","unstructured":"Obeid, D. A. et al. SARS-CoV-2 genetic diversity and variants of concern in Saudi Arabia. J. Infect. Dev. Ctries. 15(12), 1782\u20131791 (2021).","journal-title":"J. Infect. Dev. Ctries."},{"key":"8638_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ahj.2020.04.025","volume":"226","author":"JP Lang","year":"2020","unstructured":"Lang, J. P. et al. A current review of COVID-19 for the cardiovascular specialist. Am. Heart J. 226, 29\u201344 (2020).","journal-title":"Am. Heart J."},{"issue":"10285","key":"8638_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet (London, England) 397(10285), 1637 (2021).","journal-title":"Lancet (London, England)"},{"issue":"16","key":"8638_CR20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas, I. O. et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N. Engl. J. Med. 384(16), 1503\u20131516 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"8638_CR21","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 93(7), 449\u2013463 (2017).","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"8638_CR22","first-page":"949","volume":"166","author":"HM Dabbous","year":"2021","unstructured":"Dabbous, H. M. et al. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Adv. Virol. 166, 949\u2013954 (2021).","journal-title":"Adv. Virol."},{"issue":"5","key":"8638_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jinf.2020.12.005","volume":"82","author":"PJ Chen","year":"2020","unstructured":"Chen, P. J., Chao, C. M. & Lai, C. C. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients. J. Infect. 82(5), 186 (2020).","journal-title":"J. Infect."},{"issue":"12","key":"8638_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01897-20","volume":"64","author":"Y Doi","year":"2020","unstructured":"Doi, Y. et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob. Agents Chemother. 64(12), 10\u2013128 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"8638_CR25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/jmv.26308","volume":"93","author":"M Fern\u00e1ndez-Ruiz","year":"2021","unstructured":"Fern\u00e1ndez-Ruiz, M. et al. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. J. Med. Virol. 93(2), 831\u2013842 (2021).","journal-title":"J. Med. Virol."},{"issue":"2","key":"8638_CR26","first-page":"e13116","volume":"13","author":"HD Desai","year":"2021","unstructured":"Desai, H. D. et al. Predictors of mortality amongst tocilizumab administered COVID-19 Asian Indians: A predictive study from a tertiary care centre. Cureus 13(2), e13116 (2021).","journal-title":"Cureus"},{"issue":"10","key":"8638_CR27","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1016\/S2665-9913(20)30277-0","volume":"2","author":"N Biran","year":"2020","unstructured":"Biran, N. et al. Tocilizumab among patients with COVID-19 in the intensive care unit: A multicentre observational study. The Lancet Rheumatol. 2(10), e603\u2013e612 (2020).","journal-title":"The Lancet Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08638-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08638-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T08:50:41Z","timestamp":1751791841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-08638-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8638"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-08638-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,6]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The informed consent was obtained from each individual participating in the study on an electronic consent form. This study was approved by the Central Institutional Review Board at the Saudi Ministry of Health [H-01-R-009] and by individual centers\u2019 ethics boards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"24120"}}